2.020USD0.00%Mkt Cap: 48.33M USDP/E: —Last update: 2026-06-01
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synth…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap48.33M USD
Enterprise Value40.20M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.23M USD
Revenue/Share—
Last Price2.020 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.38
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B12.63
EPS (TTM)-0.98
EPS (Forward)-0.85
52W Range
1.5804% of range11.99
52W High11.99 USD
52W Low1.580 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-280.51%
ROA-158.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-24.50%
Net Debt-8.13M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.80
Quick Ratio1.72
Book Value/Sh0.1600 USD
Cash/Share0.3400 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)9.977 USD
Target Range5.000 USD – 14.91 USD
# Analysts4
Ownership
Shares Out.23.93M
Float8.57M
Insiders15.36%
Institutions58.16%
Short Interest
Short Ratio4.4d
Short % Float8.43%
Short % Out.3.69%
Shares Short883.22K
Short (prev mo.)914.99K
Technical
SMA 502.506 (-19.4%)
SMA 2005.309 (-62.0%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)168.66K
Avg Vol (10d)96.12K
Technical Indicators
RSI (14)34.1
MACD-0.1689
MACD Signal-0.0741
MACD Hist.-0.0948
BB Upper3.504 USD
BB Middle2.674 USD
BB Lower1.844 USD
BB Width62.11%
ATR (14)0.3272 USD
Vol Ratio (20d)0.67x